Biomerica (NASDAQ:BMRA) Stock Crosses Below 200-Day Moving Average – Here’s Why

Biomerica, Inc. (NASDAQ:BMRA) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.93 and traded as low as $2.46. Biomerica shares last traded at $2.6540, with a volume of 69,056 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biomerica in a report on Tuesday, October 14th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Biomerica presently has an average rating of “Sell”.

Biomerica Price Performance

The firm has a market capitalization of $7.94 million, a price-to-earnings ratio of -2.80 and a beta of 0.06. The business has a 50 day moving average of $2.54 and a 200 day moving average of $2.93.

About Biomerica

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.